Oslo University Hospital Rikshospitalet was the site of an experimental autologous dendritic cell (DC) vaccine that was tested in an open-label, Phase I/II clinical trial in Acute Myeloid Leukemia (AML) patients. With the primary outcomes announced by Munich-based...